Multicenter Interspecialty Consensus on Experimental Oncology Drug–Related Ocular Adverse Event Reporting

Are there possible improvements to the ocular Common Terminology Criteria for Adverse Events (CTCAE)?This survey study comprising a consensus panel of ophthalmologists, oncologists, and US Food and Drug Administration personnel found scales ambiguous with unreliable ocular adverse event (AE) grading leading to unclear recommendations for experimental oncology drug dose modifications. New ocular AE grading scales for visual acuity, eye symptoms, cornea, conjunctiva/sclera, anterior chamber, and retina/posterior segment were created with clear grading and associated experimental drug dose modification recommendations.These revised ocular AE grading scales may facilitate consistent reporting, standardize appropriate experimental oncology drug dose modification recommendations, and promote patient safety.

Corresponding Author: Laura J. Esserman, MD, MBA, Department of Surgery, University of California, San Francisco, 1825 4th St, 3rd Floor, San Francisco, CA 94158 (laura.esserman@ucsf.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.